ReviewVaccines2014
Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles.
Review in Vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.Current medical science · 2025Review
- Brachyury-Activated Fucoidan Hydrogel Microspheres Rejuvenate Degenerative Intervertebral Discs Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza.Vaccines · 2024Review
- mRNA vaccine development and applications: A special focus on tumors (Review).International journal of oncology · 2024Review
- Article
- RNA Combined with Nanoformulation to Advance Therapeutic Technologies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- mRNA vaccine in cancer therapy: Current advance and future outlook.Clinical and translational medicine · 2023Review
- Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review.Clinical pharmacology : advances and applications · 2023Review
- mRNA-based therapeutics: powerful and versatile tools to combat diseases.Signal transduction and targeted therapy · 2022Review
- Advances in mRNA and other vaccines against MERS-CoV.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Vaccination hesitancy and the "myth" on mRNA-based vaccines in Italy in the COVID-19 era: Does urgency meet major safety criteria?Journal of medical virology · 2021Article
- Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.Advanced healthcare materials · 2021Review
- Article
- mRNA vaccine for cancer immunotherapy.Molecular cancer · 2021Review
- Cationic HDL mimetics enhance in vivo delivery of self-replicating mRNA.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Glycan-binding profile of DC-like cells.Glycoconjugate journal · 2020Article
- Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs.Frontiers in immunology · 2020Article
- Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens.Vaccines · 2019Review
- Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine.Molecular therapy. Nucleic acids · 2019Article
- Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA.Gene therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DC) play essential roles determining efficacy of vaccine delivery with respect to immune defence development and regulation. This renders DCs important targets for vaccine delivery, particularly RNA vaccines. While delivery of interfering RNA oligonucleotides to the appropriate intracellular sites for RNA-interference has proven successful, the methodologies are identical for RNA vaccines, which require delivery to RNA translation sites. Delivery of mRNA has benefitted from application of cationic entities; these offer value following endocytosis of RNA, when cationic or amphipathic properties can promote endocytic vesicle membrane perturbation to facilitate cytosolic translocation. The present review presents how such advances are being applied to the delivery of a new form of RNA vaccine, replicons (RepRNA) carrying inserted foreign genes of interest encoding vaccine antigens. Approaches have been developed for delivery to DCs, leading to the translation of the RepRNA and encoded vaccine antigens both in vitro and in vivo. Potential mechanisms favouring efficient delivery leading to translation are discussed with respect to the DC endocytic machinery, showing the importance of cytosolic translocation from acidifying endocytic structures. The review relates the DC endocytic pathways to immune response induction, and the potential advantages for these self-replicating RNA vaccines in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.